Biotech News

C4 Therapeutics to Participate in Upcoming March Conferences

C4 Therapeutics (CCCC)C4 TherapeuticsFinancing

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in two upcoming March conferences.

TD Cowen 46 th Annual Healthcare Conference: Management will present and participate in a fireside chat on March 3, 2026, at 11:50 AM ET taking place in Boston, Massachusetts.

Barclays 28 th Annual Global Healthcare Conference: Management will participate in a fireside chat on March 10, 2026 at 8:00 AM ET taking place in Miami, Florida.

The live webcasts will be available on the Investors section of the company’s website at www.c4therapeutics.com . The archived replays of the webcasts will be available for approximately 90 days following the events.

About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO ® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com .

Contacts: Investors: Courtney Solberg Associate Director, Investor Relations [email protected]

Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy [email protected]

Related news

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

CCCCC4 Therapeutics2026-08-10 20:01 EST

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CCCCC4 Therapeutics2026-06-11 11:00 EST

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

ZNTLZentalis2026-08-17 20:01 EST

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

ZNTLZentalis2026-08-14 02:23 EST

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

REPLReplimune Group2026-08-10 12:00 EST

Replimune Announces Pricing of $150 Million Underwritten Offering

ERASErasca2026-07-15 20:01 EST

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

ERASErasca2026-07-14 03:10 EST

Erasca Announces Pricing of Upsized Public Offering of Common Stock

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

C4 Therapeutics

Targeted Protein Degradation Company C4 Therapeutics develops medicines that use the cell’s protein-disposal machinery to remove disease-causing proteins. Cemsidomide Cemsidomide is an oral molecular glue degrader of IKZF1 and IKZF3 being developed as a potential foundational therapy for multiple myeloma. Combination Strategy Clinical...

Recent company news

Stock data

Close
4.00 USD
Market cap
479.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States